Woodard Gavitt A, Kane Emma R, Todorovic Nicholas, Prince Samantha, Dacic Sanja, Chen Lieping
Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Transl Cancer Res. 2024 Nov 30;13(11):6394-6402. doi: 10.21037/tcr-24-983. Epub 2024 Nov 27.
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is expressed in 20-25% of non-small cell lung cancer (NSCLC) and there is interest in CEACAM5 as a biomarker given its potential for blood-based detection and investigational study as a drug target. Increased expression of CEACAM5 has been observed in semi-solid lung adenocarcinoma lesions, which have an increased prevalence in women and never smokers. Given this association, sex-based differences in CEACAM5 were evaluated. The Cancer Genome Atlas (TCGA) data on CEACAM5 expression in NSCLC tumors (n=994) in women (n=398) and men (n=596) were analyzed for differences in expression of CEACAM5 based on sex and histologic subtypes of adenocarcinoma and for correlations with overall survival (OS). Among all stages of NSCLC, mean expression of CEACAM5 was 143.3 fragments per kilobase of transcript per million (FPKM) with differences observed between female and male patients (194.5 109.2 FPKM, P<0.0001) and between adenocarcinoma and squamous cell carcinoma (239.3 46.2 FPKM, P<0.0001). Differences persisted among combined sex and histology subgroups. High CEACAM5 was not predictive of survival in NSCLC or adenocarcinoma overall, but was associated with worse survival among stage I female patients with adenocarcinoma (5-year OS CEACAM5 high =33% low =64%, log-rank P=0.008). Higher levels of CEACAM5 expression are observed in NSCLC tumors in female patients and adenocarcinoma histology. High CEACAM5 expression in lung adenocarcinoma is associated with worse survival among female patients. The biologic impact of sex on CEACAM5 as a biomarker warrants further study.
癌胚抗原相关细胞粘附分子5（CEACAM5）在20%-25%的非小细胞肺癌（NSCLC）中表达，鉴于其具有基于血液检测的潜力以及作为药物靶点进行研究的可能性，CEACAM5作为一种生物标志物受到关注。在女性和从不吸烟的人群中患病率增加的半实性肺腺癌病变中观察到CEACAM5表达增加。鉴于这种关联，对CEACAM5的性别差异进行了评估。分析了癌症基因组图谱（TCGA）中关于女性（n=398）和男性（n=596）NSCLC肿瘤（n=994）中CEACAM5表达的数据，以探讨基于性别和腺癌组织学亚型的CEACAM5表达差异以及与总生存期（OS）的相关性。在NSCLC的所有阶段中，CEACAM5的平均表达为每百万转录本每千碱基143.3片段（FPKM），女性和男性患者之间（194.5对109.2 FPKM，P<0.0001）以及腺癌和鳞状细胞癌之间（239.3对46.2 FPKM，P<0.0001）均观察到差异。在性别和组织学联合亚组中差异仍然存在。总体而言，高CEACAM5水平并不能预测NSCLC或腺癌的生存期，但与I期女性腺癌患者的较差生存期相关（5年OS：CEACAM5高=33%，低=64%，对数秩检验P=0.008）。在女性患者的NSCLC肿瘤和腺癌组织学中观察到更高水平的CEACAM5表达。肺腺癌中高CEACAM5表达与女性患者较差的生存期相关。性别对作为生物标志物的CEACAM5的生物学影响值得进一步研究。
